Vaccine strategy could aid in COVID-19 immunization by Benjamin Boettner, Harvard University
The vaccine platform approach is rooted in the idea that antigens, when they are incorporated together with immune-activating adjuvants in a longer-lived biomaterial scaffold that concentrates immune cells at the site of vaccination, can be presented to the immune system in a more controlled and sustained way than when merely provided transiently in soluble form. As a result of this, the immune system's protective responses can be more effective and prolonged. team of bioengineers, materials-scientists and immunologists at Harvard's Wyss Institute has developed a broadly deployable biomaterials-based infection vaccine technology called OMNIVAX. https://medicalxpress.com/news/2020-08-vaccine-strategy-aid-covid-immunization.html
Mymetics and Baylor College of Medicine start Research ... www.morningstar.com/news/accesswire/590000msn/... May 18, 2020 · Mymetics has started a Covid-19 vaccine development project based on Mymetics' virosome vaccine carrier platform, which will evaluate different rationally designed SARS-CoV-2 antigens for an
The European vaccine infrastructure, TRANSVAC2, funded by the European Commission through the Horizon 2020 framework, will provide Mymetics access to high quality technical vaccine development services in the fields of antigen production, analytics and animal models https://finance.yahoo.com/news/mymetics-receives-support-virosome-based-060000658.html
Market Data 
Markets 
AI
